Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader
B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on June 3, 2025.
Kymera Therapeutics Inc. (KYMR)
Market is closed
News
- 1 - 10
- Next >>
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT
On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51
Earlier during the company's May 9 earnings call, Kymera indicated a strong financial position with $775 million in cash, which would extend the company's operational runway into H1 2028.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621
On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript
Justine Koenigsberg: Good morning, and welcome to Kymera Therapeutics, Inc.'s Immunology Innovation Day, our virtual event to introduce our next immunology program, IRAF5.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript February 27, 2025Kymera Therapeutics, Inc. misses on earnings expectations.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. All participants will be in listen-only mode.
- 1 - 10
- Next >>
Billionaire Hedge Funds
